HIV-1 replication in the CNS, primarily in cells of the macrophage/microglial lineage [2, 3] . The mechanisms responsible for neurological damage remain poorly understood. Because neurons are not infected by HIV-1, neuronal damage has been attributed to bystander effects mediated by viral gene products or molecules secreted by astrocytes, microglia, or immune effector cells [3] [4] [5] [6] [7] . Major histocompatibility complex (MHC) class I-restricted CD8 + T cells may mediate viral clearance from the CNS but also have been implicated in immune-mediated neuronal damage [4, 8] . Thus, antiviral T cell activity within the CNS might prove beneficial but also might exacerbate CNS disease. There have been no detailed studies of T cell trafficking to the CNS in HIV-1-infected individuals. Sampling of cerebrospinal fluid (CSF) may provide a window into the study of CNS infection by means of a relatively noninvasive procedure [9, 10] . Although CSF may not fully reflect events occurring in the brain parenchyma, this method nevertheless provides a convenient means of studying a parallel compartment [11] . a Stage 0 is defined as "normal," and stage 4 is defined as end-stage dementia. This classification was first described by Price and Brew [17, 18] . b On repeat analysis, 1 patient had a WBC count of 146 cells/mm 3 . c For values !20 RNA copies/mL, calculations were performed using 19 RNA copies/mL. d Calculated as log 10 difference between plasma and CSF virus loads.
Normal CSF contains !5 white blood cells (WBCs)/mL; however, pleocytosis has been observed in many HIV-1-positive individuals, including asymptomatic subjects [12] . Plasma virus load, CSF virus load, and CSF WBC count appear to be related, particularly when plasma HIV-1 RNA levels in plasma are high [13] [14] [15] . Further evidence for this association has been found from studies of patients undergoing structured treatment interruption (STI) [10] .
To explain the relationship between high CSF virus load and pleocytosis, 2 hypotheses have been invoked [9] . The "push" hypothesis proposed that systemic infection augments lymphocyte activation and vascular permeability, leading to nonantigen-specific entry of lymphocytes and monocytes into CSF. In this model, CNS infection is viewed as secondary to systemic infection, which drives leukocyte infiltration of CSF. On a molecular level, the push hypothesis predicts that activation (including up-regulation of adhesion molecules such as leukocyte function antigen [LFA]-1 and very late antigen [VLA]-4) leads to increased extravasation of activated lymphocytes into CSF. Alternatively, a "pull" hypothesis suggests that HIV-1 infection of the CNS is the primary event and proposes that the influx of lymphocytes is a secondary response to local infection and inflammation. This model predicts that viral replication within the CNS leads to secretion of chemokines (i. [16] . These 2 models are not mutually exclusive but may be viewed as complementary.
To investigate the migration of CD8 + T cells to CSF in HIV-1-infected individuals, we assessed expression of adhesion molecules VLA-4 and LFA-1 and chemokine receptors CXCR3 and CCR5 on lymphocytes in peripheral blood and CSF samples from 19 HIV-1-positive individuals, including 6 with asymptomatic pleocytosis, and 8 healthy control subjects. We also measured levels of the chemokines IP-10, MIP-1a, MIP-1b, and RANTES in CSF and assessed the frequency and phenotype of HIV-1-specific CD8 + T cells in CSF. Our findings suggest a role for adhesion molecules and chemokines in lymphocyte trafficking to the CNS during HIV-1 disease and demonstrate that HIV-1-specific CD8 + T cells may be present in the CSF of patients without neurological symptoms. These observations indicate an ongoing inflammatory response in the CNS of HIV-1-positive individuals who do not show evidence of neurological disease.
SUBJECTS AND METHODS
Subject population. CSF and peripheral blood were obtained concurrently from 19 HIV-1-positive individuals participating in ongoing studies at San Francisco General Hospital and from 8 HIV-1-negative, healthy volunteers. Control subjects were screened by serological testing for HIV-1 antibodies. Baseline characteristics of both groups are summarized in table 1. Written informed consent was obtained from all patients, and the human experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this clinical research. Study protocols were approved by the Committee on Human Research, University of California, San Francisco. Exclusion criteria included pregnancy; presence of a brain-mass lesion that was at risk of herniation; any other contraindication to lumbar puncture (LP), such as coagulopathy; drug or alcohol abuse; and diagnosis of any severe neurological or psychiatric disorder that might confound neurological evaluation.
All HIV-1-positive subjects were clinically healthy at enrollment, were not currently undergoing antiretroviral chemotherapy, and did not have a history of CNS opportunistic infection or AIDS dementia complex stage 1 or above. Most patients had received a diagnosis of HIV-1 infection 1-15 years prior to enrollment; in some cases, the date of HIV-1 infection was not known. For some patients, additional blood and CSF samples were taken at follow-up visits; in these cases, only baseline information is reported in table 1. Neurological assessment consisted of evaluation of a standard history and an examination targeting AIDS dementia complex that also was capable of identifying other neurological conditions. Four quantitative tests were used to determine a score for neurological performance, the quantitative neurological performance battery (QNPZ)-4 score [19] . A positive score indicates performance above the so-called norm. In this study, QNPZ-4 scores for the HIV-1-infected individuals and the control subjects were not significantly different.
LP and analysis of CSF. CSF was obtained by LP using a 22-gauge Pencil Point (Sprotte) spinal needle, to minimize post-LP headache. Routine assessment included CSF WBC count, differential counts, and total protein and albumin levels. HIV-1 load in CSF supernatant and plasma was determined with the Amplicor HIV-1 Monitor system (Roche Diagnostic Systems), by use of the standard assay or its ultrasensitive modification for values !500 copies/mL. A value of 19 copies/mL was used for results below the detection limit of 20 copies/mL. Analyses of virus load were performed at the Core Virology Laboratory, Gladstone Institute of Virology and Immunology, University of California, San Francisco.
Flow cytometric analysis of cell-surface antigens. Mononuclear cells were isolated from blood by ficoll centrifugation (Pharmacia). CSF cells were obtained by low-speed centrifugation. Because of the limited number of lymphocytes present in CSF, performance of all analyses on all samples was not possible. Thus, for this exploratory study, samples were analyzed from 6-13 representative HIV-1-positive individuals for each set of phenotypic markers. For each test, 500,000 peripheral blood mononuclear cells (PBMCs) or 5-20,000 CSF cells were stained with monoclonal antibodies for 30 min at 4ЊC and then were washed, fixed in paraformaldehyde, and analyzed by flow cytometry. The monoclonal antibodies included CD3, CD4, CD8, CD45RO, CXCR3, CCR5, VLA-4 (CD49d), and LFA-1 (CD11a) conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein, and allophycocyanin (APC) (Becton-Dickinson Pharmingen). For 6-color flow cytometry, CD4 PE-Cy7 and CD8 APC-Cy7 (Caltag) and CD45RO energy-coupled dye, PE-Texas red (IOTest) also were used. Four-and six-color acquisition was performed on FACS Calibur and FACS Vantage instruments (Becton-Dickinson Pharmingen), respectively. Staining patterns were analyzed by use of Cell Quest (Becton-Dickinson Pharmingen) and FlowJo (TreeStar) software.
MHC class I tetramer staining. PBMCs were screened for HLA-A2 by means of monoclonal antibody staining (One Lambda) and flow cytometry. PBMCs from HLA-A2-positive individuals were tested with the following PE-labeled HLA-A*0201 tetrameric complexes: Gag 77-85 (SL9, SLYNTVATL) and cytomegalovirus (CMV) pp65 495-503 (NLVPMVATV) (Beckman Coulter) [20] . Results were considered to be positive if a defined population representing 10.03% of CD8 + T cells bound the tetramer. As negative controls, PBMCs were tested from individuals Chemokine analysis. After removal of cells by centrifugation, CSF and plasma samples from HIV-1-positive individuals and control subjects were assessed for levels of IP-10, MIP1a, MIP-1b, and RANTES by use of commercial ELISA kits (Quantikine, R&D Systems). Because of limited sample volume, performance of all tests on all samples was not possible. Thus, chemokine levels in a subset of samples from 10 representative HIV-1-positive individuals and 8 control subjects were analyzed. Samples were selected on the basis of availability.
Statistical analysis. All statistical analyses were performed by use of Sigma Stat and Sigma Plot software (SPSS). For comparisons between groups, Student's t tests were performed when data were normally distributed and variances were equal. When these criteria were not satisfied, nonparametric tests (i.e., MannWhitney rank sum tests) were performed. Linear regression analysis was used to assess the relationship between chemokine levels and virus load.
RESULTS
Pleocytosis associated with high CSF virus load. As shown in figure 1, CSF WBC counts were low (0-5 cells/mm 3 ) in patients with CSF virus load !5,000 copies/mL. However, patients with CSF virus load 110,000 copies/mL had CSF WBC counts of 7-39 cells/mm 3 . At a subsequent visit, 1 patient with pleocytosis had a CSF WBC count of 146 cells/mm 3 (data not shown). These findings are similar to earlier observations obtained from a larger cohort [10] . CSF lymphocytes in HIV-1-positive patients were predominantly CD8 + , whereas those in HIV-1-negative individuals were predominantly CD4 + (data not shown).
LFA-1 high CD8 + T cell trafficking to CSF. Staining of blood lymphocytes with antibodies to VLA-4 and LFA-1 revealed a complex pattern of LFA-1 expression on both CD8 + and CD8 In both subject groups, the majority of CD8 + T cells present in CSF were LFA-1 high . However, the difference in fluorescence intensity between blood and CSF was more pronounced for HIV-1-positive individuals (figure 2 ). P p .02 Expression of CXCR3 on a high percentage of CSF T cells in all subjects. Recent reports have suggested a role for the chemokine receptor CXCR3 and its ligands, IP-10 and monokine induced by interferon-g, in T cell trafficking to CSF in multiple sclerosis [21, 22] . IP-10 also has been detected in the CSF of HIV-1-positive individuals [23] . Accordingly, we assessed lymphocytes in blood and CSF for expression of CXCR3 (figure 4). In control subjects and HIV-1-positive individuals, the percentage of CD8 + lymphocytes expressing CXCR3 was higher in CSF than in blood ( ; for both groups). P ! .001 n p 8 In both groups combined, CXCR3 was expressed by 185% of CSF CD8 + T cells in 15 of the 16 individuals. Blood from HIV-1-positive individuals contained a slightly higher percentage of CXCR3 + CD8 + T cells than that from control subjects; however, the difference was not statistically significant (median, 44.5% vs. 36.7%, respectively) (figure 4). CXCR3 expression was also similar in CSF CD8 + T cells from both groups (median, 88.6% for HIV-1-positive individuals vs. 87.4% for control subjects).
Dual staining of CSF CD8 + T cells with antibodies to CXCR3 and CCR5 showed expression of both chemokine receptors in a significantly higher percentage of T cells in CSF from HIV-1-positive individuals (median, 65.4%), compared with control subjects (median, 20.1%; ) (figure 4). Thus, the ma-P p .001 jority of CD8 + T cells trafficking to CSF during HIV-1 infection expressed both CXCR3 and CCR5.
Differences between CD8 + and CD4 + lymphocytes. To di- + T cells present in CSF. By using in vitro T cell expansion and cloning, previous studies demonstrated the presence of HIV-1-specific CD8 + T cells in CSF [4, 8] . However, these studies could not provide an estimate of the frequency of antigen-specific CD8 + T cells in CSF. To determine whether HIV-1-specific CD8 + T cells could be detected directly ex vivo, we analyzed blood and CSF samples, using MHC class I tetramers [20, 24] . Of 10 patients who were positive for HLA-A*0201, 2 had CD8 + T cells specific for the HIV-1 Gag (p17, 77-85) epitope in blood and CSF (figure 5A; table 3). Both patients had plasma virus loads 140,000 copies/ mL, CSF virus loads 12500 copies/mL, and CD4 + T cell counts 1250 cells/mL. Patient A was tested on 2 occasions (2 months apart), and tetramer-binding cells were detected in CSF at similar frequencies on both dates. This patient also had mild pleocytosis on both dates (WBC count, 7 and 14 cells/mL). Patient C did not have pleocytosis.
In patients A and C, Gag-specific CD8 + T cells were present at 1.4-1.5-fold higher frequencies in CSF than in blood. Gagspecific CD8 + T cells in both compartments were predominantly CD45RO high : 80% of tetramer-binding cells in CSF and 73% in blood expressed this marker (figure 5A, center plots, top right quadrants). However, in CSF but not blood, the majority of Gag SL9-specific CD8 + T cells expressed CCR5. In patient A, CCR5 was expressed by !10% of SL9-specific cells in blood and by 150% of SL9-specific cells in CSF (figure 5A, bottom plots, top right quadrants). Together, these results suggest that HIV-1-specific CD8 + T cells with a memory phenotype (CD45RO + , CCR5 + ) circulate in CSF.
CMV-specific CD8 + T cells in CSF.
Five of 10 HLA-A2-positive patients, including patients A and C described above, had CD8 + T cells specific for the CMV pp65 peptide NLMPVATV in blood. Of these 5 patients, 4 were screened for CMV-specific T cells in CSF. Patients B and D had detectable but low-frequency populations of tetramer-binding cells in CSF ( figure 5B; table 3) . Because of the low frequency of CMVspecific cells in CSF, the level of CCR5 expression on these cells was not possible to determine. In contrast to HIV-1-specific CD8 + T cells, which were detected at higher frequencies in CSF than in blood, CMV-specific CD8 + T cells were present at frequencies 2.5-2.9-fold lower in CSF than in blood. CSF from the other 2 patients contained CMV-specific CD8 + T cells at or near the detection limit for tetramer staining; accordingly, the results of these stains were considered equivocal (data not shown) [20] .
Chemokine levels in CSF. IP-10 levels were measured in plasma and CSF from 10 HIV-1-positive individuals and 8 control subjects ( figure 6A ). The HIV-1-positive group included 3 patients with asymptomatic pleocytosis and CSF virus load 112,000 copies/mL. These patients had CSF WBC counts of 7, 31, and 39 cells/mm 3 and CSF virus loads of 13,800, 12,500, and 16,100 copies/mL, respectively. All control subjects had CSF WBC counts of 0-3 cells/mm 3 . Healthy control subjects had relatively low concentrations of IP-10 in plasma and CSF (median, 80.5 and 123.5 pg/mL, respectively). In HIV-1-positive individuals, IP-10 concentrations were significantly higher: median concentrations were 272 pg/mL in plasma ( , vs. control subjects) and 516 pg/ P p .011 mL in CSF ( , vs. control subjects) (figure 6A). In 8 P p .008 of 10 patients, CSF IP-10 concentrations were 1.3-5.1-fold higher than concentrations in plasma, resulting in a significant trend toward higher expression in CSF in the group as a whole ( ). The 3 patients with pleocytosis had the highest CSF P p .045 IP-10 concentrations: 833, 894, and 1390 pg/mL, respectively. Linear regression analysis revealed a correlation between CSF IP-10 levels and CSF virus load ( ; ) (figure 2 r p .777 P p .0007 6B). This correlation was driven predominantly by the patients with pleocytosis. These findings strongly suggest a role for IP-10 in lymphocyte trafficking to CSF during HIV-1 infection ( figure 7) . The high levels of IP-10 observed in CSF suggest intrathecal production and accumulation of this chemokine.
The CCR5 ligands MIP-1a, MIP-1b, and RANTES also were studied (data not shown). Plasma concentrations of these chemokines were similar between the HIV-1-infected and control groups. In CSF from subjects in both groups, all 3 molecules were present at extremely low concentrations that were at or near the detection threshold (i.e., р10 pg/mL). These findings are consistent with those of earlier studies of patients without AIDS dementia complex [25, 26] . Accordingly, no firm conclusions could be drawn from these data about the relevance of CCR5 ligands to CSF T cell trafficking.
DISCUSSION
Our findings demonstrate that, during chronic HIV-1 infection, the majority of CD8 + T cells trafficking to CSF have the phenotype VLA-4 high , LFA-1 high and express chemokine receptors CCR5 and CXCR3. Our results also support a role for the chemokine IP-10 in lymphocyte recruitment to CSF during asymptomatic pleocytosis associated with HIV-1 infection. Together, these observations provide a molecular basis for a comDownloaded from https://academic.oup.com/jid/article-abstract/189/12/2202/858638 by guest on 03 January 2019 bined "push-pull" model of lymphocyte trafficking to the CNS during HIV-1 infection (figure 7) [9] . The push model predicts that systemic infection leads to lymphocyte activation, including up-regulation of adhesion molecules that may participate in extravasation. The pull model suggests that lymphocyte trafficking into the CNS is a secondary response to local HIV-1 infection and inflammation and is mediated by locally secreted chemokines.
Although there have been no detailed studies of CNS lymphocyte trafficking in HIV-1 infection, studies of multiple sclerosis and meningitis have suggested that common CSF-trafficking pathways are shared by T cells in many inflammatory conditions [27] [28] [29] [30] . The brain has been regarded as an immunologically privileged site, and, until recently, leukocyte trafficking to the CNS was believed to be minimal [31] . The brain microenvironment is separated from the general circulatory system by the blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB) [32] [33] [34] . The BBB is provided by brain microvascular endothelial cells, which differ from other capillary endothelial cells by the expression of tight junctions (figure 7). The choroid plexus (CP) contains permeable ("fenestrated") capillary endothelium, and the BCSFB is provided by intercellular tight junctions of the CP epithelium (not shown). CSF is formed by filtration, primarily in the CP of the lateral, third, and fourth ventricles. Brain vessels within Virchow-Robin spaces and meningeal vessels also may contribute to the formation of CSF, particularly in inflammatory conditions.
A generalized 5-step model has been proposed to elucidate the molecular interactions required for lymphocyte extravasation across typical capillary endothelia (reviewed in [35] ). The steps outlined in this model are as follows: (1) tethering, (2) rolling, (3) G protein-coupled activation, (4) arrest, and (5) extravasation. LFA-1, or aLb2 integrin, can mediate arrest via interactions with intercellular adhesion molecule (ICAM)-1 and Ϫ2. VLA-4, or a4b1 integrin, can participate in rolling and arrest through interactions with vascular cell adhesion molecule (VCAM)-1 on endothelial cells [35] . Lymphocytes entering CSF may also traverse the CP epithelium. The molecular interactions involved in this process have not been thoroughly studied; however, ICAM and VCAM are not highly expressed at the basolateral surface (capillary side) of CP epithelia [32, 33] . Lymphocytes entering the brain across BBB endothelia or entering CSF via the CP encounter tight junctions associated with the BBB and BCSFB. The process by which these junctions become destabilized during an inflammatory response is not well understood; however, locally produced cytokines and matrix metalloproteases are believed to play an important role (reviewed in [34] ).
The role of chemokines in lymphocyte trafficking to the CNS during HIV-1 infection has not been studied extensively. Our results demonstrate that HIV-1-positive individuals with pleocytosis have significantly higher levels of CSF IP-10 than do control subjects. CSF IP-10, monocyte chemotactic protein (MCP)-1, and RANTES levels are also elevated in some HIV- 1-positive individuals with CNS disease [23, 36] . The high levels of these chemokines in CSF suggest local production within the CNS (figure 7). Two HIV-1 proteins, Tat and gp120, have been implicated in the induction of chemokine production by astrocytes and microglia [25, [37] [38] [39] [40] . CD8 + T cells that enter the CNS are another potential source of chemokines and might participate in auto recruitment [41] . Prospective studies will be required to determine whether CNS production of IP-10 and/or asymptomatic pleocytosis may be predictors of eventual HIV-1-related dementia.
It has been known for many years that activated lymphocytes are able to cross the BBB [31, 42] , and early experiments demonstrated that lymphocytes activated in vitro could traverse an intact BBB [42, 43] . However, persistence of T cells in the brain is believed to depend on the presence of cognate antigen [31, 42] . Studies of experimental autoimmune encephalomyelitis in rodents demonstrated that activated T cells specific for antigens expressed in the CNS (e.g., myelin basic protein) were selectively retained, whereas activated T cells with irrelevant specificities (e.g., ovalbumin or tuberculin) could enter the CNS but would not accumulate there.
The trafficking patterns of antigen-specific T cells remain somewhat obscure, despite advances in our understanding of chemotaxis and lymphocyte extravasation [35, 44, 45] . The advent of MHC class I-tetramer staining has resulted in moresensitive, accurate assessments of antigen-specific T cell frequency [20, 24, [46] [47] [48] . In this study, 2 of 10 HLA-A*0201-positive individuals had HIV-1 Gag-specific, CD8 + T cells in blood; both had slightly higher frequencies of Gag-specific, CD8 + T cells in CSF. These preliminary findings suggest that HIV-1-specific CD8 + T cells may accumulate in the CNS because of the presence of viral antigen [45] .
Two additional HLA-A*0201-positive patients were found to have CMV-specific CD8 + T cells in CSF. Interestingly, these cells were present at a 2-3-fold lower frequency in CSF than in blood. The primary reservoir for CMV replication in the body is not known, but capillary endothelial cells and monocyte/macrophage progenitors in bone marrow may be important sites [49, 50] . In the absence of actively replicating CMV in the brain, CMV-specific CD8 + T cells may circulate through the CP but may avoid accumulating in the CNS.
Our findings support a push-pull model for lymphocyte traf-ficking to CSF during HIV-1 infection ( figure 7 ). In this model, systemic infection may lead to increased lymphocyte activation and vascular permeability, including up-regulation of adhesion molecules such as LFA-1 and VLA-4 that facilitate lymphocyte extravasation into CSF. The pull component of this model is provided by viral replication within the CNS, leading to local production of chemokines (primarily IP-10 during asymptomatic pleocytosis) that attract lymphocytes expressing the cognate receptor CXCR3 [16, 40] . In addition, activated astrocytes and microglia can secrete several cytokines (e.g., interferon-g, tumor necrosis factor-a, and interleukin-1b) that modulate expression of adhesion molecules (e.g., ICAM and VCAM) and also may play a role in the remodeling of tight junctions, thus facilitating lymphocyte extravasation [51] [52] [53] . The presence of HIV-1 antigen in the CNS may lead to retention and accumulation of HIV-1-specific CD8 + T cells. Together, these findings suggest that similar mechanisms of CNS homing and retention are utilized by lymphocytes in a variety of infectious and autoimmune diseases.
